Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis

Zhou,Hong; Feng,Xiao-Ling; Zhang,Hong-Ying; Xu,Fei-Fei; Zhu,Jie

doi:10.3892/etm.2013.1238

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis

Authors:
- Hong Zhou
- Xiao-Ling Feng
- Hong-Ying Zhang
- Fei-Fei Xu
- Jie Zhu
View Affiliations

Affiliations: Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China
Published online on: July 30, 2013 https://doi.org/10.3892/etm.2013.1238
Pages: 1034-1040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Coronary heart disease (CHD) is the leading cause of mortality worldwide. Previous studies have suggested that cilostazol‑based triple antiplatelet therapy (TAT) may be more effective than conventional dual antiplatelet therapy (DAT) at improving the clinical outcomes of patients with CHD undergoing percutaneous coronary intervention (PCI). However, individually published results are inconclusive. The present meta‑analysis evaluated controlled clinical studies to compare the clinical outcomes between TAT and DAT in patients with CHD undergoing PCI. Ten controlled clinical studies were included, with a total of 7,670 patients with CHD undergoing PCI. The total number included 3,925 patients treated with DAT (aspirin and clopidogrel) and 3745 patients treated with TAT (addition of cilostazol to DAT). The crude odds ratio (OR) with a 95% confidence interval (CI) was calculated with either the fixed or random effects model. The meta‑analysis results indicated that patients in the TAT group had a significantly lower rate of restenosis compared with that of the DAT group (OR=0.59, 95% CI: 0.45‑0.77; P<0.001). The rate of major adverse cardiac events (MACE) and target lesion revascularization (TLR) in the TAT group were significantly lower compared with those in the DAT group (MACE: OR=0.69, 95% CI: 0.56‑0.85, P<0.001; TLR: OR=0.61, 95% CI: 0.43‑0.88, P=0.008). However, no significant differences between the TAT and DAT groups in terms of mortality rate, myocardial infarction, target vessel revascularization and stent thrombosis were observed. In conclusion, the results of the present meta‑analysis indicated that the efficacy and safety of cilostazol-based TAT therapy is greater than that of conventional DAT therapy for patients with CHD undergoing PCI.

View Figures

View References

1.	Aradi D, Komócsi A, Price MJ, et al: Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol. Jun 15–2012.(Epub ahead of print).
2.	Meryon I, Patel N, Millane T and Varma C: Normal coronary angiography and primary percutaneous coronary intervention for ST elevation myocardial infarction: a literature review and audit findings. Int J Clin Pract. 64:1245–1251. 2010. View Article : Google Scholar
3.	Mercado N and Serruys PW: A meta-analytical approach for the treatment of in-stent restenosis. Eur Heart J. 24:217–218. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Meier B, Bachmann D and Lüscher T: 25 years of coronary angioplasty: almost a fairy tale. Lancet. 361:5272003.PubMed/NCBI
5.	Mrdovic I, Savic L, Lasica R, et al: Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels. 28:424–433. 2013. View Article : Google Scholar
6.	Gurbel PA and Tantry US: Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol. 19:439–448. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Takahashi S, Kaneda H, Tanaka S, et al: Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J. 71:226–228. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Suh JW, Lee SP, Park KW, et al: Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 57:280–289. 2011.
9.	Regensteiner JG and Stewart KJ: Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med. 3:604–610. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Jeong YH, Lee SW, Choi BR, et al: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 53:1101–1109. 2009.
11.	Tamhane U, Meier P, Chetcuti S, et al: Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 5:384–393. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Lee SW, Park SW, Hong MK, et al: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 46:1833–1837. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
15.	DerSimonian R and Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 28:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
17.	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Ahn CM, Hong SJ, Park JH, Kim JS and Lim DS: Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels. 26:502–510. 2011.PubMed/NCBI
19.	Chen YD, Lu YL, Jin ZN, Yuan F and Lu SZ: A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl). 119:360–366. 2006.PubMed/NCBI
20.	Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al: Coronary stent restenosis in patients treated with cilostazol. Circulation. 112:2826–2832. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Han Y, Li Y, Wang S, et al: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 157:733–739. 2009. View Article : Google Scholar
22.	Kim JY, Lee K, Shin M, et al: Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J. 71:1867–1872. 2007. View Article : Google Scholar
23.	Lee SW, Chun KJ, Park SW, et al: Comparison of triple anti-platelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol. 105:168–173. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Lee SW, Park SW, Kim YH, et al: A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 57:1264–1270. 2011.
25.	Lu YL, Chen YZ, Lv SZ, Pan WZ and Liu X: Cilostazol prevention in elderly coronary heart disease patients with coronary bare metal stent restenosis after effect. Chin J Geriatr. 25:537–538. 2006.(In Chinese).
26.	Schleinitz MD, Olkin I and Heidenreich PA: Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J. 148:990–997. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Smith SC Jr, Dove JT, Jacobs AK, et al: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 103:3019–3041. 2001.
28.	Singh I, Shafiq N, Pandhi P, et al: Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol. 68:4–13. 2009. View Article : Google Scholar
29.	Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 155:1081–1089. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Friedland SN, Eisenberg MJ and Shimony A: Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol. 109:1397–1404. 2012. View Article : Google Scholar : PubMed/NCBI
31.	Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS and Lim DS: Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hyper-tensive type 2 diabetic patients. Heart. 97:1425–1432. 2011.
32.	Hashiguchi M, Ohno K, Nakazawa R, Kishino S, Mochizuki M and Shiga T: Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther. 18:211–217. 2004. View Article : Google Scholar : PubMed/NCBI